Merck, Pfizer drug combo extends kidney cancer survival: study

Nearly 90 percent of patients who received the combination therapy were still alive after 12 months compared with about 78 percent of patients who were alive after a year when treated with the older drug Sutent, data showed.Merck on Monday released interim data from the trial, saying the combination reduced the risk of death by 47 percent compared with Sutent.The findings add to an arsenal of positive clinical data forKeytruda, which is approved to treat several types of cancer, making it by far